Bevacizumab BS IV infusion 400mg “CTNK”, manufactured by Nippon Kayaku, contains Bevacizumab (genetical recombination) [Bevacizumab follow-on 4]. This monoclonal antibody works by inhibiting vascular endothelial growth factor A (VEGF-A), thereby preventing the growth of new blood vessels that supply tumors. It is provided as 400mg in 16mL per bottle, with YJ code 4291463A2027.
Bevacizumab BS IV infusion 400mg “CTNK”
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →